The post Lenovo Unleashes AI-Powered Creativity and Productivity Devices and Solutions at CES 2024 appeared first on AiThority.

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.

Recommended AI News: WiMi Developed RPSSC Technology With Multiple Advantages in Hyperspectral Image Processing

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum”

Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade. By leveraging its unique Foundation Model, Paige has surpassed these limitations. With data derived from over 4 million digitized slides, Paige’s innovative approach removes the constraints of developing single tissue products, making it possible to efficiently create cancer detection AI applications across a multitude of tumor types, a first in AI-based cancer diagnosis.

“The early success of our Foundation Model has been possible due to the size, quality, and diversity of the datasets we used to build it,” said Siqi Liu, PhD, director of AI Science at Paige. “Paige has access to one of the largest and most highly regarded pathology datasets globally, which allows us to leverage cutting-edge deep-learning approaches to train systems to detect common, complex, and even very rare cancer entities. Paige’s development provides the pathology community with the most powerful tools for diagnosis, prognosis, biomarker development, and targeted selection of patients for precision therapy,” he continued.

The exceptional performance of Paige’s multi-cancer application across various tissue types is considered state-of-the art in cancer pathology AI. Paige is committed to ensuring its AI applications are clinical grade and will therefore continue to seek FDA regulatory oversight for products based on the Foundation Model technology.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

“We see FDA clearance as being critical to ensure that regulatory and safety standards are being upheld in the application of AI in cancer diagnostics across tumor types,” said Andy Moye, CEO of Paige. “Paige remains at the forefront of innovation and regulatory milestones, and we expect this multi-tissue detection model to benefit patients, pathologists, and the broader medical community. Our commitment to excellence is exemplified by this groundbreaking achievement, marking a significant leap forward in cancer diagnostics.”

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum,” said Razik Yousfi, Senior Vice President of Technology at Paige. “By combining the outputs of the Foundation Model with data types from other modalities, including genomics, radiology, and other health data, one can derive exponentially greater insights about the nature of cancer, its behavior, and response to specific treatments.”

Recommended AI News: OPENLANE Launches Visual Boost AI to Pinpoint Vehicle Damage

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types appeared first on AiThority.

The post SurveyMonkey Announces New Trends in Business, Culture, and Social appeared first on AiThority.

The post Dexios Chooses Maverick Medical AI as Its AI Medical Coding Solution appeared first on AiThority.

New offering enables pharma brands to engage in 24/7, MLR-compliant near-human interaction with ideal customers in the moment of need

Swoop, a leader in developing precise direct to consumer (DTC) and healthcare provider (HCP) audiences for pharmaceutical and life sciences brands, announced the launch of its AI-powered conversational agent. This groundbreaking advancement in healthcare marketing sets a new standard for lower funnel engagement, enabling immediate, MLR-compliant virtual customer interactions via brand.com.

Recommended AI News: Trust Stamp Partners With Scurid to Deliver AI-Powered In-Field Authentication

“Swoop’s AI-powered conversational agent marks the first groundbreaking advancement for brand.com since the introduction of pharmaceutical websites in the 1990s, addressing a pressing need for innovation in how the industry engages with their customers”

“Swoop’s AI-powered conversational agent marks the first groundbreaking advancement for brand.com since the introduction of pharmaceutical websites in the 1990s, addressing a pressing need for innovation in how the industry engages with their customers,” said Scott Rines, underscoring the historic significance of this achievement. “Patients and physicians are looking for real-time information, 24/7/365 during their moment of need, but are often faced with an overwhelming experience on brand.com. They come to the site seeking fast, clear answers to their health-related questions – our agent solves this.”

Market conditions continue to remain a challenge with shortages of healthcare professionals despite an uptick in customer demand for information related to their condition and treatment decisions. Meanwhile, HCPs are also less likely to allow medical reps into their offices, a shift that has continued post-Covid. Instead, these increasingly digital-native, often over-extended, physicians prefer to seek information online when their schedule permits, limiting the impact of personal promotion.

“The ability to parse the data derived from lower funnel conversations with HCPs and patients in real time will prove invaluable, as these signals will become proprietary 1st party data to optimize future marketing spend and messaging,” added Rines.

Recommended AI News: Level Access Agrees to Acquire UserWay

Key Features of Swoop’s Conversational Agent:

• Dynamic Patient Conversations: Patients and HCPs can engage with conversational AI in real-time, creating a personalized and responsive user experience to drive more high-value actions on a health brand website.
• MLR-Approved Medical Information: Leveraging advanced algorithms, conversational AI provides MLR-approved answers to both simple and complex medical questions in the moment of need, enhancing the overall user experience for both patients and HCPs.
• Real-Time Patient Insights: Valuable real-time data from conversations accessible via dashboards allows healthcare brands to assess the effectiveness of their messaging and make informed adjustments promptly.
• Scalable to Client Demands: Whether for a single brand, therapeutic area or product portfolio, Swoop conversational AI agents can scale with the needs of healthcare marketers from new product launches to covering open territories and unsupported brands.
• Patient Data Security and Compliance: Swoop prioritizes patient privacy and data security, ensuring that all conversational AI agents operate in compliance with the highest industry standards and regulations.

Typical Client Results Seen by Customers:

• 96% – Average answer success rate of inquiries
• 5.2 minutes – Typical conversation duration
• 4.7/5 – Average user satisfaction rating
• 800% – Increase in high-value activities on brand websites

Swoop’s conversational AI technology is built on more than 1.3 billion conversations with patients and providers and has been trained under the supervision of physicians and medically trained clinicians. Unlike generative AI, which can hallucinate and is not appropriate for direct patient and HCP interaction in the heavily regulated pharmaceutical industry, Swoop conversational AI uses fine-tuned large language models to understand user intent and surface the most relevant MLR-approved answers to ensure compliance, accuracy and, most importantly, safety.

Recommended AI News: Trust Stamp Partners With Scurid to Deliver AI-Powered In-Field Authentication

[To share your insights with us, please write to sghosh@martechseries.com]

The post Swoop Launches AI-Powered Healthcare Conversation Agent That Revolutionizes brand.com Engagement appeared first on AiThority.

Nanotronics, the Industrial AI company announced a new strategic partnership with OrbiMed, a leading global life sciences investment firm. As part of the transaction, OrbiMed is investing in Nanotronics’ proprietary technology to advance quality control and precision manufacturing across the healthcare and biotech industries.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

“AI is redrawing the healthcare landscape and the ability to optimize workflows, automate inspection, and reduce costs associated with R&D and manufacturing will result in better pharmaceutical quality, build more resilient supply chains, and reduce problems with production such as contamination”

“AI is redrawing the healthcare landscape and the ability to optimize workflows, automate inspection, and reduce costs associated with R&D and manufacturing will result in better pharmaceutical quality, build more resilient supply chains, and reduce problems with production such as contamination,” said Matthew Rizzo, General Partner of OrbiMed. “We are confident that our investment in Nanotronics will help manufacturers across the healthcare spectrum increase yields and decrease their carbon footprint.”

“As Nanotronics continues to expand on the industries we serve globally, we are pleased to place a stronger emphasis on improving manufacturing quality and production for the industries advancing the future of our humanity,” says CEO and cofounder, Matthew Putman. “The sooner healthcare companies embrace Artificial Intelligence for manufacturing and quality control, the quicker we will see improved patient outcomes.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

Nanotronics is an Industrial AI company that deploys advanced optical solutions to optimize manufacturing procedures, effectively refining, and expediting assembly for any industry relying on a precision process for production. Nanotronics uses hardware and software solutions to clean, sort, and manage existing data as well as data collected in real-time across sensors placed strategically within customers’ plants. This data is stored on local servers to ensure maximum security. Nanotronics’ sophisticated AI system correlates data points into actionable insights for manufacturers to correct flaws in the production process while also predicting future errors. This results in an autonomous factory that will drive up yields, decrease waste, and encourage implementation of ESG standards. Nanotronics helps customers bring lab experimentation and R&D innovation to devise scalable business solutions and advance our industrial future.

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post OrbiMed Invests in Strategic Partnership With Nanotronics appeared first on AiThority.

BrainChip Holdings Ltd the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI IP, and NVISO Group Ltd, a global leader in human behavior AI software, will showcase a joint system that enables more advanced, more capable and more accurate AI on consumer products at the Consumer Electronics Show (CES) 2024 in Las Vegas, Nevada.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

“In our goal to driving machines to understand people and their behaviors, we have partnered with BrainChip to develop a high-performance system that enables efficient and effective human interaction with intelligent systems”

NVISO Group’s technology is uniquely able to analyze signals of human behavior such as facial expressions, emotions, identity, head poses, gaze, gestures, activities, and objects with which users interact. BrainChip’s Akida™ IP and processors address the need for high levels of efficient AI performance and on-chip learning, with ultra-low power technologies.

In combining NVISO Group AI Human Behavioral Software and BrainChip’s Akida neuromorphic compute, the resulting system monitors the state of the users through real-time perception and observation of head and body pose, eye tracking and gaze, as well as indicates emotion reasoning.

“In our goal to driving machines to understand people and their behaviors, we have partnered with BrainChip to develop a high-performance system that enables efficient and effective human interaction with intelligent systems,” said Virpi Pennanen, CEO of NVISO Group. “This system will be deployable across a variety of consumer-level products at the Edge to enable autonomous machines to improve the quality of life in a safe and secure way.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

“Since first partnering with NVISO Group, we have worked diligently to combine our synergistic technologies to create intelligent systems that can interface with humans by recognizing and interpreting movement through the power of artificial intelligence,” said Rob Telson, Vice President of Ecosystem and Partnerships at BrainChip. “We are pleased to be able to demonstrate our progress at CES and show attendees how they can utilize our platforms for Edge AI devices to better improve the human experience.”

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post BrainChip and NVISO Group Demonstrate AI-Enabled Human Behavioral Analysis at CES 2024 appeared first on AiThority.

WellBe Senior Medical, an in-home value-based care provider to the Medicare Advantage population, announced an investment from CVS Health Ventures, the corporate venture capital arm of CVS Health. This strategic partnership and investment will help to accelerate WellBe’s national expansion. Today, WellBe operates in seven states, has over 107,000 Medicare Advantage members and over $2 billion in premium under management, and is the fastest-growing independent provider of value-based care in the home for Medicare Advantage.

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

The company’s rapid growth underscores the critical need for better solutions and investment in senior healthcare. “CVS Health Ventures is committed to helping provide seamless access to quality health care, especially for vulnerable populations like seniors,” says Vijay Patel, Managing Partner of CVS Health Ventures. “WellBe’s innovative approach to in-home medical care aligns with our vision of redefining the way health care is delivered in a multi-payor, patient-centric manner. Our collaboration with WellBe will support their mission to empower seniors to live healthier, happier lives in their homes.”

WellBe’s prescribing providers bring specialized geriatric care into the patient’s home. Many of the services available from a typical physician clinic are now delivered to the home, proactively managing care for the sickest and most complex Medicare Advantage patients. WellBe partners with Medicare Advantage health plans via global capitated risk arrangements to manage the ten to fifteen percent of members with very high and rising medical loss ratios. This allows WellBe to guarantee savings up front to the health plan and take on the risk of managing this costly population. By delivering proactive medical care at home, available to patients 24/7/365, WellBe’s best-in-class model helps avoid unnecessary hospitalizations, reducing total medical cost while improving overall patient satisfaction. Additionally, WellBe improves HEDIS ­­measures leading to an increase in Star Ratings from a low of 2.5 to a high of 4.5.

WellBe was cofounded by Chicago Pacific Founders (CPF) and provided the capital to grow WellBe to this point. CPF invests in founder-led healthcare services companies and helps drive healthcare services innovation forward. “WellBe has proven its ability to significantly improve the quality and health outcomes for the sickest and most frail in our communities,” said Mary Tolan, Founder and Managing Partner of CPF. “We are passionate about WellBe’s commitment to providing the level of care we want for our family members and loved ones. The patient outcomes speak profoundly of the company.”

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

“All of us have had an elderly friend or family member whose health increased in complexity with age, limiting every aspect of their life,” said Dr. Jeffrey Kang, Founder and CEO of WellBe Senior Medical. “This makes traditional office-based care inconvenient, unresponsive, and often unavailable when it’s needed. Instead of trying to bring these frail patients to the care, the solution is to brin­­g the care to the patient, in the comfort of their own home. We’ve found that WellBe can provide more than 90 percent of what occurs in a primary care doctor’s office conveniently at home. Access to WellBe’s in-home geriatric care should be available to everyone, which is why we’re passionate about partnering with payors nationwide, removing yet another barrier to care for patients. This collaboration with CVS Health Ventures fuels our mission to share our proven care model with more payors, more communities, and more patients.”

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post WellBe Senior Medical Secures Investment from CVS Health Ventures to Accelerate Nationwide Expansion appeared first on AiThority.

Medable Inc., the leading technology provider for modern clinical trials, announces new intelligent automation technology applied across its clinical trials platform to cut standard trial build timelines by at least half. Early application of the technology in electronic clinical outcomes assessment (eCOA) deployments – a major delay to study startup industry-wide – is groundbreaking. By automating laborious, manual tasks such as testing, Medable saves substantial time and removes eCOA from the critical path to trial go-live.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines by 50% #clinicaltrials #ai #clinicalresearch #studystartup #biosciences #healthcare #drugdevelopment

Medable’s new AI and automation capabilities catapult the company to the forefront of automating clinical trial operations and align with the industry’s perennial need to launch studies faster. Now, sponsors can eliminate common gridlocks caused by conversion, configuration, validation, and quality engineering. Top-10 global pharmaceutical companies are already benefiting from Medable’s novel technology, shaving weeks off build times.

As part of a broader roadmap incorporating AI and intelligent automation, Medable’s updated eCOA capabilities include an auto-configuration tool that produces standard configurations, such as schedules of assessments, anchor dates, and patient flags, in minutes. Medable’s auto-validate tool also eliminates weeks of tedious testing to automatically deliver a downloadable Configuration Validation Report (CVR) that validates the quality of study builds.

“We are reimagining the way clinical trials are deployed by eliminating many of the biggest process bottlenecks,” said Michelle Longmire, CEO and co-founder of Medable. “Starting with eCOA, we are accelerating clinical trials while helping to improve data quality – ultimately enabling our vision of a one-day study start-up to help deliver effective treatments and cures to patients faster. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively.

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Medable’s Intelligent Automation Capabilities Reduce Clinical Trial Technology Deployment Timelines appeared first on AiThority.

• The anticipated acquisition aligns to GE HealthCare’s precision care strategy with the goal of strengthening the company’s digital solutions across care pathways

• MIM Software provides AI-enabled image analysis and workflow tools across multiple care areas, including oncology, urology, neurology, and cardiology

• Today’s agreement reinforces GE HealthCare’s commitment to integrate medical imaging products in order to deliver more precise, connected and efficient care across disease states

GE HealthCare announced it has entered into an agreement to acquire MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

“We are excited by the prospect of joining GE HealthCare and thrilled to share this exciting news”

Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital. These efforts are reflected in the company’s mission to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier.

MIM Software’s portfolio of innovative imaging solutions provides a variety of beneficial features, including: the integration of diagnostic images from multiple modalities into treatment plans; automation to help reduce repetitive tasks and manual interventions; quantitation and advanced processing in diagnostic imaging and nuclear medicine to help determine therapy response; and a platform to assist with Theranostics imaging and dosimetry.

GE HealthCare expects to integrate MIM Software solutions into its advanced visualization offerings to facilitate AI-based segmentation and contouring as well as dosimetry analysis for patients across their treatment journeys and in the growing fields of radiology, molecular imaging, and radiation oncology.

“We are committed to providing comprehensive, connected devices and digital solutions that enable providers to improve patient care across multiple specialties,” says Peter Arduini, President & CEO of GE HealthCare. “We expect our efforts to bring these two complementary organizations and innovative product portfolios together to strengthen our capabilities as a leading provider of integrated imaging systems, analytics, and advanced digital workflows across several care areas and pathways – including Theranostics, radiation oncology, urology, neurology and cardiology. Now and in the future, we are working to transform patient care.”

“We are excited by the prospect of joining GE HealthCare and thrilled to share this exciting news,” adds Andrew Nelson, CEO of MIM Software. “Over the past two decades, we have worked to develop innovative vendor agnostic products and deliver quality services to earn the trust of our customers – this will not change. As a part of GE HealthCare, we anticipate developing new and increasingly integrated digital solutions to meet our customers’ most complex and pressing needs, today and into the future. Together, we will build upon our shared legacies of enhancing patient care.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

As novel therapies become more widely available, providers rely on advanced imaging, workflow and digital solutions to provide critical information and help enable faster, more effective treatment plans. With the agreement to acquire MIM Software, GE HealthCare is working towards strengthening its focus and offerings to support the broad practice of precision care across various disease states and imaging practices, including Theranostics in oncology for the treatment of advanced prostate cancer, streamlined workflow solutions in radiation oncology to help simplify complex cancer treatment plans, beta amyloid imaging in neurology for the diagnosis and monitoring of Alzheimer’s patients, and myocardial perfusion to diagnose coronary artery disease (CAD).

“Our anticipated acquisition of MIM Software will mark a key moment in the evolution of our technology. By integrating MIM Software’s cutting-edge imaging analytics and AI-driven solutions with GE HealthCare’s advanced medical technology, we are not just expanding our capabilities, but joining together to embrace the possibilities of precision care. This intended merger is a fusion of innovative visions, aimed at evolving the way we detect, treat, and manage disease,” shares Taha Kass-Hout, MD, MS, Chief Technology Officer of GE HealthCare. “GE HealthCare is committed to developing smart, AI-powered devices that cater to specific disease states, thereby enabling clinicians to deliver more personalized care. We expect the integration of MIM Software will also advance our efforts in connecting data across care pathways. It is a leap towards a future where healthcare is more precise, connected, and efficient, with the goal of benefitting providers and patients worldwide.”

Founded in 2003, MIM Software is headquartered in Cleveland, Ohio, with additional offices in China and Belgium. The consummation of the transaction is subject to customary closing conditions, including regulatory approvals. Financial details of the transaction have not been disclosed publicly. GE HealthCare intends to fund this transaction with cash on hand. The Company expects this transaction to be neutral to Adjusted EBITⁱ in year one and accretive thereafter.

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post GE Healthcare Announces Agreement to Acquire MIM Software appeared first on AiThority.